By Debdeep Gupta | 17 Dec, 2024
Brokerage Radar: Morgan Stanley 'Underweight' on Wipro, JM Financial initiates coverage on Piramal Pharma with 'Buy'
Morgan Stanley On WiproUnderweight Call, Target At `250/ShAfter Capco (2021) & Rizing (2022) Acquisition, See Applied Value Tech Acqn Being Relatively SmallSee The Acqn Supporting More Of Capability Boost & Adding Some Marquee Clients To PortfolioGiven Small Scale, See Acquisition Having A Limited Impact On Financials In FY25/FY26CLSA On ITTCS, Infosys & Wipro, In Their Quarterly Preview, Showed C...
Live Comments
sonya 2024-10-24 13:57:12
results are good I presume. waiting for breakout in upperside
Login & Reply Like(0) Dislike(0) Repost SpamINVESTINGPOWER 2023-01-06 19:01:35
last year they gave dividend in q3.. this year not there looks like..
Login & Reply Like(0) Dislike(0) Repost SpamPreeti 2022-07-06 15:56:55
Buy SRF, target price Rs 2765: JM Financial . .
Login & Reply Like(0) Dislike(0) Repost SpamPalkin 2021-09-22 12:50:14
We ve long felt that the only value of stock forecasters is to make fortune tellers look good
Login & Reply Like(0) Dislike(0) Repost Spam